|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Fixed maturities (amortized cost: $91,485, $82,372, and $82,704) | ||||||||||||||||||||
| Short-term investments (amortized cost: $1,978, $2,103, and $10,005) | ||||||||||||||||||||
| Total available-for-sale securities | ||||||||||||||||||||
| Nonredeemable preferred stocks (cost: $292, $517, and $419) | ||||||||||||||||||||
| Common equities (cost: $870, $775, and $819) | ||||||||||||||||||||
| Total equity securities | ||||||||||||||||||||
| Total investments | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash and cash equivalents | ||||||||||||||||||||
| Total cash, cash equivalents, restricted cash, and restricted cash equivalents | ||||||||||||||||||||
| Accrued investment income | ||||||||||||||||||||
| Premiums receivable, net of allowance for credit losses of $544, $501, and $552 | ||||||||||||||||||||
| Reinsurance recoverables | ||||||||||||||||||||
| Prepaid reinsurance premiums | ||||||||||||||||||||
| Deferred acquisition costs | ||||||||||||||||||||
| Property and equipment, net of accumulated depreciation of $1,381, $1,369, and $1,460 | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Intangible assets, net of accumulated amortization of $170.0, $153.1, and $158.6 | ||||||||||||||||||||
| Net federal deferred income taxes | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| Unearned premiums | ||||||||||||||||||||
| Loss and loss adjustment expense reserves | ||||||||||||||||||||
| Dividends payable on common shares | ||||||||||||||||||||
| Accounts payable, accrued expenses, and other liabilities | ||||||||||||||||||||
| Debt | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Shareholders' Equity | ||||||||||||||||||||
| Serial Preferred Shares, Series B, no par value (cumulative, liquidation preference of $1,000 per share) (authorized, issued, and outstanding 0 and 0.5) | ||||||||||||||||||||
| Common shares, $1.00 par value (authorized 900; issued 798, including treasury shares of 217, 212, and 212) | ||||||||||||||||||||
| Paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive income (loss): | ||||||||||||||||||||
| Net unrealized gains (losses) on fixed-maturity securities | ||||||||||||||||||||
| Net unrealized losses on forecasted transactions | ||||||||||||||||||||
| Foreign currency translation adjustment | ||||||||||||||||||||
| Total accumulated other comprehensive income (loss) | ||||||||||||||||||||
| Total shareholders’ equity | ||||||||||||||||||||
| Total liabilities and shareholders’ equity | ||||||||||||||||||||
Loading...
